Library Subscription: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Published 6 issues per year

ISSN Print: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Gastric Retentive Dosage Forms: A Review

Volume 20, Issue 6, 2003, 28 pages
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i6.30
Get accessGet access

ABSTRACT

Gastric retentive dosage forms have been investigated to provide controlled release therapy for drugs with reduced absorption in the lower gastrointestinal (GI) tract or for local treatment of diseases of the stomach or upper GI tract. Gastric retentive dosage forms rely on either natural GI physiology, such as floating or large tablets that depend on delayed emptying from the fed stomach, or those dosage forms that are designed to fight the physiology and avoid emptying in the fasted state through dosage forms of even larger sizes with or without flotation or bioadhesion. To understand the behavior of the dosage forms, an introduction to GI motility and its measurement is provided. Because the fed mode underlies the successful development of dosage forms that rely on size or flotation, the emptying of these dosage forms in the fed mode and identification of the key factors influencing the variability of gastric retention are discussed. The design and limitations of size or density-based fed mode, and mucoadhesive and expandable fasting-state gastric retentive systems are presented.

CITED BY
  1. Schwartz Sherwyn L, Wu Jacqueline F, Berner Bret, Metformin extended release for the treatment of Type 2 diabetes mellitus, Expert Opinion on Pharmacotherapy, 7, 6, 2006. Crossref

  2. Gomez-Orellana Isabel, Strategies to improve oral drug bioavailability, Expert Opinion on Drug Delivery, 2, 3, 2005. Crossref

  3. Kagan Leonid, Hoffman Amnon, Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations, Expert Opinion on Drug Delivery, 5, 6, 2008. Crossref

  4. Schwartz Sherwin L, Gordi Toufigh, Hou Eddie, Cramer Marilou, Heritier Michelle, Cowles Verne E, Clinical development of metformin extended-release tablets for type 2 diabetes: an overview, Expert Opinion on Drug Metabolism & Toxicology, 4, 9, 2008. Crossref

  5. Berner Bret, Cowles Verne E, Case studies in swelling polymeric gastric retentive tablets, Expert Opinion on Drug Delivery, 3, 4, 2006. Crossref

  6. Lewin Andrew, Lipetz Robert, Wu Jacqueline, Schwartz Sherwyn, Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study, Clinical Therapeutics, 29, 5, 2007. Crossref

  7. Gordi Toufigh, Hou Eddie, Kasichayanula Sreeneeranj, Berner Bret, Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: A randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects, Clinical Therapeutics, 30, 5, 2008. Crossref

  8. Tao Yunying, Lu Yifan, Sun Yinjing, Gu Bing, Lu Weiyue, Pan Jun, Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability, International Journal of Pharmaceutics, 378, 1-2, 2009. Crossref

  9. Omidian Hossein, Park Kinam, Oral Targeted Drug Delivery Systems: Gastric Retention Devices, in Oral Controlled Release Formulation Design and Drug Delivery, 2010. Crossref

  10. Davis Stanley S., Formulation strategies for absorption windows, Drug Discovery Today, 10, 4, 2005. Crossref

  11. Kagan Leonid, Hoffman Amnon, Selection of drug candidates for gastroretentive dosage forms: Pharmacokinetics following continuous intragastric mode of administration in a rat model, European Journal of Pharmaceutics and Biopharmaceutics, 69, 1, 2008. Crossref

  12. Audu Momohmumuni, Umale Adikwu Michael, Chinnedu Ibezim Emmanuel, Formulation and evaluation the bioadhesive properties of drug delivery system based on PEGylated mucin matrices, Asian Pacific Journal of Tropical Medicine, 3, 6, 2010. Crossref

  13. Ali Shamsa, Fonseca Vivian, Overview of metformin: special focus on metformin extended release, Expert Opinion on Pharmacotherapy, 13, 12, 2012. Crossref

  14. Argoff Charles E, Chen Cuiping, Cowles Verne E, Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview, Expert Opinion on Drug Delivery, 9, 9, 2012. Crossref

  15. Cowles Verne E., Gordi Toufigh, Hou Sui Yuen Eddie, Steady-State Pharmacokinetics of Gabapentin after Administration of a Novel Gastroretentive Extended-Release Formulation in Postmenopausal Women with Vasomotor Symptoms, Clinical Drug Investigation, 32, 9, 2012. Crossref

  16. Chen Cuiping, Cowles Verne E., Sweeney Michael, Stolyarov Igor D., Illarioshkin Sergey N., Pharmacokinetics and Pharmacodynamics of Gastroretentive Delivery of Levodopa/Carbidopa in Patients With Parkinson Disease, Clinical Neuropharmacology, 35, 2, 2012. Crossref

  17. Chen Cuiping, Han Chien-Hsuan (Sara), Sweeney Michael, Cowles Verne E., Pharmacokinetics, Efficacy, and Tolerability of a Once-Daily Gastroretentive Dosage Form of Gabapentin for the Treatment of Postherpetic Neuralgia, Journal of Pharmaceutical Sciences, 102, 4, 2013. Crossref

  18. Chen Cuiping, Cowles Verne E., Sweeney Mike, Stolyarov Igor D., Illarioshkin Sergey N., Pharmacokinetics of Levodopa/Carbidopa Delivered From Gastric-Retentive Extended-Release Formulations in Patients With Parkinson's Disease, The Journal of Clinical Pharmacology, 52, 7, 2012. Crossref

  19. Chen Cuiping, Cowles Verne E., Hou Eddie, Pharmacokinetics of Gabapentin in a Novel Gastric-Retentive Extended-Release Formulation: Comparison With an Immediate-Release Formulation and Effect of Dose Escalation and Food, The Journal of Clinical Pharmacology, 51, 3, 2011. Crossref

  20. Prajapati Vipul D., Jani Girish K., Khutliwala Tohra A., Zala Bhumi S., Raft forming system—An upcoming approach of gastroretentive drug delivery system, Journal of Controlled Release, 168, 2, 2013. Crossref

  21. Sugihara Hikaru, Matsui Yuji, Takeuchi Hirofumi, Wilding Ian, Connor Alyson, Abe Kazuya, Nishiura Akio, Development of a gastric retentive system as a sustained-release formulation of pranlukast hydrate and its subsequent in vivo verification in human studies, European Journal of Pharmaceutical Sciences, 53, 2014. Crossref

  22. Pinkerton JoAnn V., Kagan Risa, Portman David, Sathyanarayana Rekha, Sweeney Michael, Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause, Menopause, 21, 6, 2014. Crossref

  23. Awasthi Rajendra, Kulkarni Giriraj T., Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand?, Drug Delivery, 23, 2, 2016. Crossref

  24. Bardonnet P.L., Faivre V., Pugh W.J., Piffaretti J.C., Falson F., Gastroretentive dosage forms: Overview and special case of Helicobacter pylori, Journal of Controlled Release, 111, 1-2, 2006. Crossref

  25. Kagan Leonid, Lapidot Noa, Afargan Michel, Kirmayer David, Moor Eytan, Mardor Yael, Friedman Michael, Hoffman Amnon, Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans, Journal of Controlled Release, 113, 3, 2006. Crossref

  26. Kagan L., Hoffman A., Biopharmaceutical aspects of gastro-retentive dosage forms: the gabapentin paradigm, Journal of Drug Delivery Science and Technology, 19, 4, 2009. Crossref

  27. Kyada C., Ranch K., Shah D., Optimization of Mucoadhesive Microspheres of Acyclovir by Applying 32 Full Factorial Design, Journal of Drug Delivery Science and Technology, 24, 1, 2014. Crossref

  28. Verhagen Metman Leo, Stover Natividad, Chen Cuiping, Cowles Verne E., Sweeney Michael, Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease, Movement Disorders, 30, 9, 2015. Crossref

  29. Irving Gordon, Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians, Therapeutic Advances in Chronic Disease, 3, 5, 2012. Crossref

  30. Singh Bhupinder, Chakkal Sukhwinder Kaur, Ahuja Naveen, Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology, AAPS PharmSciTech, 7, 1, 2006. Crossref

  31. Mahalingam Ravichandran, Jasti Bhaskara, Birudaraj Raj, Stefanidis Dimitrios, Killion Robert, Alfredson Tom, Anne Pratap, Li Xiaoling, Evaluation of Polyethylene Oxide Compacts as Gastroretentive Delivery Systems, AAPS PharmSciTech, 10, 1, 2009. Crossref

  32. Scholes Peter, Zann Vanessa, Lin Wu, Roe Chris, Berner Bret, Oral Site-Directed Drug Delivery and Influence on PK, in Drug Delivery Approaches, 2021. Crossref

  33. Irving Gordon, Once-daily gastroretentive gabapentin for treatment of postherpetic neuralgia, Pain Management, 2, 3, 2012. Crossref

  34. Zhao Cheng, Cai Lijun, Chen Hanxu, Tan Hui, Yan Dewen, Oral biomaterials for intestinal regulation, Engineered Regeneration, 2, 2021. Crossref

  35. Yin Lifang, Qin Chao, Chen Kaisheng, Zhu Chunli, Cao Hui, Zhou Jianping, He Wei, Zhang Qiang, Gastro-floating tablets of cephalexin: Preparation and in vitro/in vivo evaluation, International Journal of Pharmaceutics, 452, 1-2, 2013. Crossref

  36. Schwartz Sherwyn, Fonseca Vivian, Berner Bret, Cramer Marilou, Chiang Yu-Kun, Lewin Andrew, Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes, Diabetes Care, 29, 4, 2006. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain